News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Sara Brucker

Articles by Sara Brucker

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

ByMichelino De Laurentiis,Jason Mouabbi,Seock-Ah Im,Megan Kruse, MD,Stephen Chia,Sara Brucker,Cristian Villanueva,Guy Jerusalem,Melissa Gao,Gary Sopher,Jiwen Wu,Juan Pablo Zarate,J. Thaddeus Beck

May 11th 2026

Latest Updated Articles

Trending on CancerNetwork

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)

122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer